Business
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2024 and provided a business update and description of operational highlights during the year.
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ","length":161,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules ","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the year","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86% of patients showing a reduction in surgery of 50% or greater in year 2; data to be included in BLA submission","length":271,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":663,"olType":false}]},{"val":[{"type":"text","content":"Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAb) targeting COVID-19 were well tolerated and exhibited long-lasting in vivo production ","length":213,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"DMAb technology has the potential to overcome traditional monoclonal antibody production challenges, such as short half-life and anti-drug immune responses, making it a potentially promising platform for a broad range of diseases","length":229,"tagName":"p"}]},{"val":[{"type":"text","content":"DNA Medicine technology has the potential to provide long term production of therapeutic antibodies and deliver a broad spectrum of therapeutic proteins that could be used to treat diseases with missing or defective proteins","length":224,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":453,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":1490,"olType":false},{"type":"text","content":"PLYMOUTH MEETING, Pa., March 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA m...